<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527357</url>
  </required_header>
  <id_info>
    <org_study_id>FC-004</org_study_id>
    <nct_id>NCT01527357</nct_id>
  </id_info>
  <brief_title>A Study of Fibrocaps™ in Surgical Bleeding</brief_title>
  <acronym>FINISH-3</acronym>
  <official_title>A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as
      compared to gelatin sponge alone, for achieving hemostasis.

      The investigational products were used in participants with mild to moderate surgical
      bleeding during spine, liver, vascular or soft tissue surgery, when control of mild to
      moderate bleeding by standard surgical techniques is ineffective and/or impractical.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2012</start_date>
  <completion_date type="Actual">June 1, 2013</completion_date>
  <primary_completion_date type="Actual">April 24, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery</measure>
    <time_frame>Within 5 minutes</time_frame>
    <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Hemostasis (TTH) for Participants Receiving Vascular Surgery</measure>
    <time_frame>Within 5 minutes</time_frame>
    <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Hemostasis (TTH) for Participants Receiving Hepatic Resection</measure>
    <time_frame>Within 5 minutes</time_frame>
    <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Hemostasis (TTH) for Participants Receiving Soft Tissue Dissection</measure>
    <time_frame>Within 5 minutes</time_frame>
    <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restricted Mean TTH</measure>
    <time_frame>Within 5 minutes</time_frame>
    <description>Restricted mean TTH over 5 minutes is computed using Irwin's estimator, based on data collected by surgery type and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Within 29 days</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence (including clinically significant changes in laboratory values or other clinical tests) experienced by a participant administered a pharmaceutical product regardless of causal relationship with the treatment. A TEAE is any adverse event reported on the case report form that occurs after start of treatment or any adverse event with a missing start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Require Alternative Hemostatic Agents at 5 Minutes</measure>
    <time_frame>At 5 minutes</time_frame>
    <description>If hemostasis is not achieved within 5 minutes, the treatment is considered to have failed, and the surgeon is to implement additional hemostatic measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Red Blood Cells</measure>
    <time_frame>Within 29 days</time_frame>
    <description>Red blood cells are defined as including World Health Organization (WHO) DRUG terms of &quot;Blood cells, packed human&quot;, &quot;Blood, whole&quot;, &quot;Red blood cells&quot;, &quot;Red blood cells, concentrated&quot; and &quot;Red blood cells, leucocyte depleted&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">721</enrollment>
  <condition>Mild or Moderate Surgical Bleeding</condition>
  <arm_group>
    <arm_group_label>Fibrocaps + Gelatin Sponge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single application of Fibrocaps plus gelatin sponge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelatin Sponge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single application of gelatin sponge alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibrocaps</intervention_name>
    <description>Human fibrinogen and thrombin powder, for topical administration.</description>
    <arm_group_label>Fibrocaps + Gelatin Sponge</arm_group_label>
    <other_name>PRO-0601</other_name>
    <other_name>Fibrin sealant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gelatin sponge</intervention_name>
    <description>Absorbable gelatin sponge for topical administration.</description>
    <arm_group_label>Fibrocaps + Gelatin Sponge</arm_group_label>
    <arm_group_label>Gelatin Sponge</arm_group_label>
    <other_name>Gelfoam</other_name>
    <other_name>Spongostan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has signed an institutional review board/independent ethics committee
             (IRB/IEC)-approved informed consent document

          2. Is undergoing one of the 4 surgical procedures described

          3. Is at least 18 years old at time of consent

          4. If female and of child-bearing potential, has negative pregnancy test during screening
             and is not breast-feeding

          5. If able to reproduce, agrees to use a medically accepted form of contraception from
             the time of consent to completion of all follow-up study visits when engaging in
             heterosexual intercourse

          6. Has not received blood transfusion between screening and study treatment

          7. Has mild to moderate surgical bleeding

          8. Does not have intra-operative complications

          9. Has not used a topical hemostat containing thrombin prior to study treatment

         10. Has an approximate bleeding site surface area of less than or equal to 100 cm^2

        Exclusion Criteria:

          1. Has known antibodies or hypersensitivity to thrombin or other coagulation factors

          2. Has history of heparin-induced thrombocytopenia (only for vascular subjects where
             heparin use is required)

          3. Has known allergy to gelatin sponge

          4. Is unwilling to receive blood products

          5. Has liver enzymes appropriate for the study, considering their disease

          6. Has appropriate level of platelets per liter (PLT/L) during screening

          7. Has any clinically-significant coagulation disorder that may interfere with the
             assessment of efficacy or pose a safety risk to the subject according to the
             Investigator, or baseline abnormalities during screening that are not explained by
             current drug treatment (e.g., warfarin, heparin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio-Thoracic Surgeons, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Interventional Specialists of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Neurological Institute</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Colorado</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Orthopedics</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Research Institute</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Health System</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Muir MD Spine Surgery</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian Hospital/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma - Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Hospital &amp; Clinics</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Sciences Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's Research Options</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlake Hospital Medical Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Orthopaedic Specialists, P.S.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Neuroscience Center of Washington</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Militair Hospitaal Koningin Astrid</name>
      <address>
        <city>Brussells</city>
        <zip>1120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Parc Leopold, Service de Neurochirurgie</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme, Service de Neurochirurgie</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent, Gasto-Intestinale Heelkunde</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven, Abdominale Heelkunde</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <zip>4800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Arnhem</name>
      <address>
        <city>Velp</city>
        <zip>0</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital Vascular Department</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <state>England</state>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <state>England</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <results_first_submitted>December 5, 2019</results_first_submitted>
  <results_first_submitted_qc>December 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <disposition_first_submitted>April 14, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 7, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 23, 2014</disposition_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrin sealant</keyword>
  <keyword>thrombin</keyword>
  <keyword>fibrinogen</keyword>
  <keyword>hemostasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    <mesh_term>Fibrin Foam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from May 2012 to April 2013 at 57 investigative sites (United States, n = 28; United Kingdom, n = 12; The Netherlands, n = 11; and Belgium, n = 6), and were randomized 2:1 to receive treatment with Fibrocaps plus gelatin sponge or gelatin sponge alone.</recruitment_details>
      <pre_assignment_details>After screening, 719 eligible participants had surgery in 1 of 4 surgical indications (i.e., spinal, hepatic, vascular, or soft tissue dissection) on Day 1 according to local standard practice, and received treatment with the investigational product assigned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fibrocaps + Gelatin Sponge</title>
          <description>Single application of Fibrocaps plus gelatin sponge.</description>
        </group>
        <group group_id="P2">
          <title>Gelatin Sponge</title>
          <description>Single application of gelatin sponge alone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="482"/>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Efficacy Population</title>
              <participants_list>
                <participants group_id="P1" count="480">Two participants did not receive study treatment.</participants>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="465"/>
                <participants group_id="P2" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Day 29 Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Fibrocaps + Gelatin Sponge</title>
          <description>Single application of Fibrocaps plus gelatin sponge.</description>
        </group>
        <group group_id="B2">
          <title>Gelatin Sponge</title>
          <description>Single application of gelatin sponge alone.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="482"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="721"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="14.44"/>
                    <measurement group_id="B2" value="58.1" spread="14.12"/>
                    <measurement group_id="B3" value="57.6" spread="14.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="422"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="632"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery</title>
        <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
        <time_frame>Within 5 minutes</time_frame>
        <population>Efficacy population consists of all participants who were randomized, received study treatment, and had a TTH assessment. Number analyzed is the number of participants in the efficacy population who receive each type of surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery</title>
          <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
          <population>Efficacy population consists of all participants who were randomized, received study treatment, and had a TTH assessment. Number analyzed is the number of participants in the efficacy population who receive each type of surgery.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis (TTH) for Participants Receiving Vascular Surgery</title>
        <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
        <time_frame>Within 5 minutes</time_frame>
        <population>Efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis (TTH) for Participants Receiving Vascular Surgery</title>
          <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
          <population>Efficacy population</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.50" upper_limit="2.50"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis (TTH) for Participants Receiving Hepatic Resection</title>
        <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
        <time_frame>Within 5 minutes</time_frame>
        <population>Efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis (TTH) for Participants Receiving Hepatic Resection</title>
          <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
          <population>Efficacy population</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.50" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis (TTH) for Participants Receiving Soft Tissue Dissection</title>
        <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
        <time_frame>Within 5 minutes</time_frame>
        <population>Efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis (TTH) for Participants Receiving Soft Tissue Dissection</title>
          <description>The measurement of TTH begins at t=0, which is the time the study product is applied to the Target Bleeding Site (TBS) and ends when hemostasis is achieved or 5-minutes, whichever occurs first, based on data collected by surgery type and treatment.</description>
          <population>Efficacy population</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.00" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restricted Mean TTH</title>
        <description>Restricted mean TTH over 5 minutes is computed using Irwin's estimator, based on data collected by surgery type and treatment.</description>
        <time_frame>Within 5 minutes</time_frame>
        <population>Efficacy population. Number analyzed is the number of participants with data available for analysis in each surgery type.</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Restricted Mean TTH</title>
          <description>Restricted mean TTH over 5 minutes is computed using Irwin's estimator, based on data collected by surgery type and treatment.</description>
          <population>Efficacy population. Number analyzed is the number of participants with data available for analysis in each surgery type.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spinal Surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.08"/>
                    <measurement group_id="O2" value="2.7" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.14"/>
                    <measurement group_id="O2" value="3.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic Resection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.09"/>
                    <measurement group_id="O2" value="2.5" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Soft Tissue Dissection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.09"/>
                    <measurement group_id="O2" value="3.1" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</title>
        <description>An adverse event (AE) is any untoward medical occurrence (including clinically significant changes in laboratory values or other clinical tests) experienced by a participant administered a pharmaceutical product regardless of causal relationship with the treatment. A TEAE is any adverse event reported on the case report form that occurs after start of treatment or any adverse event with a missing start date.</description>
        <time_frame>Within 29 days</time_frame>
        <population>Safety population, defined as all participants who were randomized and received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</title>
          <description>An adverse event (AE) is any untoward medical occurrence (including clinically significant changes in laboratory values or other clinical tests) experienced by a participant administered a pharmaceutical product regardless of causal relationship with the treatment. A TEAE is any adverse event reported on the case report form that occurs after start of treatment or any adverse event with a missing start date.</description>
          <population>Safety population, defined as all participants who were randomized and received study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Require Alternative Hemostatic Agents at 5 Minutes</title>
        <description>If hemostasis is not achieved within 5 minutes, the treatment is considered to have failed, and the surgeon is to implement additional hemostatic measures.</description>
        <time_frame>At 5 minutes</time_frame>
        <population>Efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Require Alternative Hemostatic Agents at 5 Minutes</title>
          <description>If hemostasis is not achieved within 5 minutes, the treatment is considered to have failed, and the surgeon is to implement additional hemostatic measures.</description>
          <population>Efficacy population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Required Red Blood Cells</title>
        <description>Red blood cells are defined as including World Health Organization (WHO) DRUG terms of &quot;Blood cells, packed human&quot;, &quot;Blood, whole&quot;, &quot;Red blood cells&quot;, &quot;Red blood cells, concentrated&quot; and &quot;Red blood cells, leucocyte depleted&quot;.</description>
        <time_frame>Within 29 days</time_frame>
        <population>Efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrocaps + Gelatin Sponge</title>
            <description>Single application of Fibrocaps plus gelatin sponge.</description>
          </group>
          <group group_id="O2">
            <title>Gelatin Sponge</title>
            <description>Single application of gelatin sponge alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Red Blood Cells</title>
          <description>Red blood cells are defined as including World Health Organization (WHO) DRUG terms of &quot;Blood cells, packed human&quot;, &quot;Blood, whole&quot;, &quot;Red blood cells&quot;, &quot;Red blood cells, concentrated&quot; and &quot;Red blood cells, leucocyte depleted&quot;.</description>
          <population>Efficacy population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of surgery (Day 1) through Day 29 (End of Study)</time_frame>
      <desc>Safety population, defined as all participants who were randomized and received study treatment. All treatment-emergent serious adverse events are listed, whether or not they are related to study product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fibrocaps + Gelatin Sponge</title>
          <description>Single application of Fibrocaps plus gelatin sponge.</description>
        </group>
        <group group_id="E2">
          <title>Gelatin Sponge</title>
          <description>Single application of gelatin sponge alone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastroduodenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Small intestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Unintentional medical device removal by patient</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Small-for-size liver syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anaesthetic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Anastomotic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pancreatic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pseudomeningocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="426" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

